Kisunla (donanemab) has already been granted market approval in the United States, but in late March, the Europe's medicines regulator (EMA) issued a different assessment.
Kisunla has been developed to slow the progression of Alzheimer's disease in adult patients with amyloid-beta plaques in the brain and mild cognitive impairment or mild dementia due to Alzheimer's disease.
BREAKING